Moleculin Biotech (NASDAQ:MBRX – Get Free Report) will post its quarterly earnings results after the market closes on Friday, May 10th. Analysts expect Moleculin Biotech to post earnings of ($3.59) per share for the quarter.
Moleculin Biotech Stock Up 5.1 %
MBRX opened at $4.94 on Thursday. The firm has a market capitalization of $11.00 million, a P/E ratio of -0.36 and a beta of 1.85. The stock’s 50 day moving average price is $6.19 and its two-hundred day moving average price is $7.86. Moleculin Biotech has a 12-month low of $4.28 and a 12-month high of $15.75.
Analyst Ratings Changes
Several analysts have recently weighed in on the company. Roth Mkm reissued a “buy” rating and set a $40.00 price objective on shares of Moleculin Biotech in a report on Friday, April 12th. StockNews.com began coverage on Moleculin Biotech in a report on Tuesday. They set a “sell” rating on the stock. Finally, Maxim Group cut their target price on Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 26th.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
Featured Articles
- Five stocks we like better than Moleculin Biotech
- Consumer Staples Stocks, Explained
- Roblox: The Bottom Just Fell Out of the Metaverse
- Comparing and Trading High PE Ratio Stocks
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- What is Put Option Volume?
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
